WELLESLEY HILLS, Massachusetts, March 29, 2011 /PRNewswire/ --
Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Source Precision Medicine, Inc., d/b/a Source MDx ("Source MDx") announced that 16 molecular diagnostic development programs will be offered for sale on April 29, 2011.
These molecular diagnostic programs are blood-based, not tissue-based. Eight programs cover the following cancers: prostate, lung, breast, cervical, ovarian, colon, bladder and melanoma. In addition, two programs cover infectious diseases: sepsis and hepatitis C infection; three programs cover autoimmune diseases: rheumatoid arthritis, multiple sclerosis, lupus, osteoarthritis and ocular and one covers transplant rejection.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office - firstname.lastname@example.org or +1-781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm Finn, Warnke & Gayton LLP of Wellesley Hills, Massachusetts (http://www.finnwarnkegayton.com). He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as Assignment for the Benefit of Creditors and Liquidating Agent for corporations. He has been involved in a number of loan workouts and bankruptcy cases for thirty-six (36) years. His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Epix Pharmaceuticals, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at +1-781-237-8840.
SOURCE Joseph F. Finn, Jr., C.P.A.